ClinicalTrials.gg
RecruitingNCT05022030CAPCETUpdated Mar 7, 2024

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

A Phase 2 interventional study of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab in Colo-rectal Cancer, Capecitabine and Cetuximab, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies testing cetuximab in Colonic Neoplasms — 7 open to participants now, 12 under way, 4 of them phase 3. Cetuximab · Colonic Neoplasms.

Planned enrollment
14th of 56
150 · median 46
Started
2021
with 2 others
Phase 2
34 of 58
5 open now
Primary completion
2025-06
later than 4 of 11 live
Registered
51st of 58
by date

Among the 58 studies testing cetuximab in Colonic Neoplasms, this one is the 14th largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2021, is one of 34 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 51st registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

7 of the 58 studies testing cetuximab in Colonic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing cetuximab in Colonic Neoplasms, or all of them as a file.
02

Study summary

This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF genes.

Read the detailed description

The patients, who meet the inclusion criteria and have signed the informed consent, will be randomly assigned (1:1 ratio) to receive mCapOX plus cetuximab regimen (arm A) and mFOLFOX6 plus cetuximab regimen (arm B).

03

Conditions studied

  • Colo-rectal Cancer
  • Capecitabine
  • Cetuximab

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written and can understand and comply with the requirements of the study;
  • Men and women ≥ 18 years of age;
  • Patients with or cytologically confirmed left-sided colorectal adenocarcinoma with wild-type RAS and BRAF genes;
  • Presence of at least one evaluable lesion, as defined in Version 1.1;
  • With an (ECOG) performance status of ≤ 1;
  • No palliative chemotherapy, targeted, immunotherapy, or prior platinum-based chemotherapy, relapse more than 12 months from the end of adjuvant chemotherapy;
  • According to the imaging findings and surgical assessment of initial unresectable, synchronous metastatic colorectal cancer, no serious complications of the primary tumor (obstruction, perforation, massive hemorrhage that cannot be treated in internal medicine, etc.) ;
  • of longer than 3 months ( clinical assessment);
  • Requirements for lab indicators neutrophils ≥ 1.5 × 109/L, ≥ 75 × 109/L, ≥ 8 g/dL, total ≤ 1.5 × (UNL); ASAT () and/or ALAT (SGPT) ≤ 2.5 × UNL (≤ 5 × UNL if liver metastases); alkaline phosphatase ≤ 2.5 × UNL (≤ 5 × UNL if liver metastases, ≤ 10 × UNL if bone metastases); LDH \< 1500 U/L; (calculated according to Cockcroft and Gault formula) > 50 mL/min or serum creatinine ≤ 1.5 × UNL;

Exclusion criteria

Exclusion Criteria:

  • Patients with mCRC who were initially resectable with R0 resection or radiofrequency or SBRT were excluded.
  • Patients diagnosed with MSI-H or dMMR by PCR or immunohistochemistry
  • to any therapeutic agent.
  • Patients who received chemotherapy containing oxaliplatin and fluorouracil within 12 months before entering the study;
  • Patients who have failed one or more palliative chemotherapy regimens;
  • Patients with uncontrolled virus
  • Peripheral neuropathy ≥ CTC grade 2;
  • Neurological or psychiatric disorders affecting cognitive performance;
  • Patients with central nervous system could not be controlled with radiotherapy;
  • Previous enteritis, chronic diarrhea, or recurrent bowel obstruction; uncontrolled bleeding from internal medicine; bowel perforation
  • Uncontrolled concomitant diseases within 6 months before the study, including unstable angina, acute myocardial infarction, cerebrovascular accident, etc.;
  • Pregnant or lactating patients, or those of who do not take adequate measures;
  • History of other , but no disease-free survival longer than 5 years;
  • Patients concurrently receiving other anti-tumor treatment or participating in other interventional clinical trials;
  • Patients who are unable to comply with this study for psychological, family or social reasons.
  • Patients with other serious diseases that the investigator considers not suitable.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Arm A

    mCapOX (capecitabine+oxaliplatin) plus cetuximab

    Drug: mCapOX plus cetuximab

  • Active comparator
    Arm B

    mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab

    Drug: mFOLFOX6 plus cetuximab

Interventions

  • DrugmCapOX plus cetuximab

    Drug page: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w

  • DrugmFOLFOX6 plus cetuximab

    oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) rate at 9 months

    PFS rate at 9 months is defined as the proportion of patients without PD or death at 9 months after randomization.

    Time frame: 9 months

Secondary outcomes

  1. Objective response rate

    The rate of complete response and partial response

    Time frame: 6 months

  2. Disease control rate

    The rate of complete response, partial response and stable disease.

    Time frame: 6 months

  3. Progression free survival

    Progression free survival is defined as the period from randomization to disease progress or death.

    Time frame: up to 3 years

  4. Overall survival

    Overall survial is defined as the period from randomization to death.

    Time frame: up to 4 years

  5. Adverse event rate

    The rate of adverse event after treatment

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jun 2025, 46 months after the start.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 46 months is close to that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Aug 26, 2021
StartActual
Jul 21, 2021
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2026
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05022030
Collaborators
First Affiliated Hospital of Chongqing Medical University
Responsible party
Meng Qiu (Dr., West China Hospital) — Principal investigator
First posted
Aug 26, 2021
Start date
Jul 21, 2021
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Mar 7, 2024

Study contacts

Xiaofen Li, M.D.
Contact
lxf0827@163.com
+86-28-85422589
Meng Qiu, M.D.
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion